Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

OPDP Director Tom Abrams cautions against reading into the “snapshot.”


Related Content

Identifying Deceptive Rx Advertising: FDA Rejects PhRMA's Criticisms Of Its Study
FDA Lull In Rx Promotion Citations Continues; Guidances May Be Bigger Priority
FDA Closes 2013 With Flurry Of Citations For Misleading Rx Promotions
FDA Gives Thumbs Down To Amgen’s Film Noir Aranesp Promo
Will Aegerion Need Another TV Interview To Satisfy FDA After Juxtapid Citation?
FDA’s Biggest DTC Advertising Study Eyes Online Promotion
Xarelto Ad’s Benefit Claims Need Renal Caveats, FDA Says
FDA's First "Bad Ad" Citation Goes To Hill Dermaceuticals
Quality of Life Claims In Sanctura Journal Advertisement Cited By FDA


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts